US 12,269,853 B2
Modified human erythropoietin
Marcos Oggero-Eberhardt, Rafaela-Pcia. de Santa Fe (AR); Maria de los Milagros Burgi-Fissolo, Santa Fe-Pcia. de Santa Fe (AR); Aquiles Dorella, San Carlos de Bariloche-Pcia. de Rio N (AR); Gabriela I. Aparicio, Villa Bosch-Pcia. de Buenos Aire (AR); Marina Etcheverrigaray, Santa Fe-Pcia. de Santa Fe (AR); Camila Scorticati, Ciudad Autonoma de Buenos Aires (AR); and Ricardo Kratje, Santa Fe-Pcia. de Santa Fe (AR)
Assigned to UNIVERSIDAD NACIONAL DEL LITORAL, Santa Fe. de Santa Fe (AR); CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), Ciudad Autonoma de Buenos Aires (AR); and UNIVERSDAD NACIONAL DE GENERAL SAN MARTIN
Appl. No. 17/280,541
Filed by UNIVERSIDAD NACIONAL DEL LITORAL, Santa Fe-Pcia. de Santa Fe (AR); CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), Ciudad Autonoma de Buenos Aires (AR); and UNIVERSDAD NACIONAL DE GENERAL SAN MARTIN, Billinghurst-Pcia. de Buenos Aires (AR)
PCT Filed Sep. 26, 2019, PCT No. PCT/IB2019/058179
§ 371(c)(1), (2) Date Mar. 26, 2021,
PCT Pub. No. WO2020/065576, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 20180102793 (AR), filed on Sep. 27, 2018.
Prior Publication US 2022/0220177 A1, Jul. 14, 2022
Int. Cl. C07K 14/505 (2006.01); A61P 25/28 (2006.01); C12N 15/85 (2006.01)
CPC C07K 14/505 (2013.01) [A61P 25/28 (2018.01); C12N 15/85 (2013.01)] 3 Claims
 
1. A modified mature human erythropoietin with erythropoietic activity less than 0.5% in relation to a native erythropoietin, which maintains its neuroprotective and neuroplastic capacity, comprising mutations of a binding site to a homodimeric or heterodimeric receptor through the addition of consensus sites for glycosylation, the mutations comprising:
Lys45Asn and Asn47Thr, wherein said modified mature human erythropoietin comprises SEQ ID NO: 4.